Free Trial

Eterna Therapeutics Q4 2023 Earnings Report

Eterna Therapeutics logo
$0.25 +0.00 (+1.05%)
(As of 12/20/2024 05:31 PM ET)

Eterna Therapeutics EPS Results

Actual EPS
-$1.14
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Eterna Therapeutics Revenue Results

Actual Revenue
$0.02 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Eterna Therapeutics Announcement Details

Quarter
Q4 2023
Time
N/A

Conference Call Resources

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

>> Register for the Workshop Now

Eterna Therapeutics Earnings Headlines

Eterna Therapeutics Inc Ordinary Shares
Eterna launches research to evaluate ERNA-101
What most folks don’t know about oil (BIG missed opportunity)
$1 Trillion… That’s how much Big Tech is set to spend on AI investment in the coming months—according to Goldman Sachs. This investment is driving an A.I. boom that’s being felt across many industries… Including a specific group of energy tickers since A.I. data centers use a massive amount of power. One of those tickers is CEG, up nearly 600% in the last 3 years… Combined with the upcoming presidential election, we have the recipe for a major shakeup in the market. You see, each time the U.S. elects a new president, one overlooked part of the energy sector tends to see a big move. Fact is… this energy niche is BOOMING.
Eterna Therapeutics Announces Up to $1 Million Stock Repurchase Program
Eterna regains compliance with Nasdaq
See More Eterna Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Eterna Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eterna Therapeutics and other key companies, straight to your email.

About Eterna Therapeutics

Eterna Therapeutics (NASDAQ:ERNA), a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

View Eterna Therapeutics Profile

More Earnings Resources from MarketBeat

Upcoming Earnings